Secretary's Advisory Committee on Genetics, Health, and Society

Seventh Meeting
June 15 - 16, 2005
North Bethesda, MD

A G E N D A

Wednesday, June 15, 2005

8:30 a.m. - 8:45 a.m.	Opening Remarks Reed Tuckson, M.D. SACGHS Chair
8:45 a.m. – 10:15 a.m.	**Session on Genetic Discrimination**
8:45 – 9:00	*Update on SACGHS Efforts* Agnes Masny, R.N., M.P.H., M.S. Chair, SACGHS Genetic Discrimination Task Force
9:00 – 9:30	*Overview of Legal Analysis* Peter S. Gray, J.D. Equal Employment Opportunity Commission
9:30 – 10:00	*Congressional Update* Ms. Jaimie Vickery Legislative Assistant Office of the Honorable Judy Biggert U.S. House of Representatives
10:00 – 10:15	Full Committee Discussion Facilitators: Ms. Masny and Dr. Tuckson
10:15 a.m. – 10:30 a.m.	BREAK
10:30 a.m. – 11:30 a.m.	**Direct-to-Consumer Marketing of Genetic Tests**
10:30 – 10:45	Secretary Leavitt's Response to SACGHS Letter and Relevant Agency Activities Dr. Tuckson and Relevant *Ex Officios*

10:45 – 11:15	*FDA's Role in the Oversight of Direct-to-Consumer Marketing of Genetics Tests* Deborah Wolf, J.D. Office of Compliance Center for Devices and Radiological Health, FDA
11:15 – 11:30	Full Committee Discussion
11:30 a.m. – 12:00 p.m.	**Update on SACGHS' Work on the Large Population Studies Issue** Facilitator: Hunt Willard, Ph.D. Chair, SACGHS Large Population Studies Task Force
12:00 p.m. – 1:00 p.m.	LUNCH
1:00 p.m. – 1:30 p.m.	Public Comments
1:30 p.m. – 5:30 p.m.	**Coverage and Reimbursement of Genetic Tests and Services**
1:30 – 2:00	*Overview of Public Comments on SACGHS' Draft Report* Cynthia Berry, J.D. Chair, SACGHS Coverage and Reimbursement Task Force
2:00 – 3:45	Full Committee Discussion of Draft Report Facilitator: Ms. Berry
3:45 – 4:00	BREAK
4:00 – 5:30	Finalization of Draft Report and Recommendations Facilitator: Ms. Berry

Thursday, June 16, 2005

8:30 a.m. – 5:00 p.m.	**Current Issues in Pharmacogenomics**
8:30 – 8:40	Session Overview and Goals Emily Winn-Deen, Ph.D. Chair, SACGHS Pharmacogenomics Task Force
8:40 – 9:00	*Fundamentals of Pharmacogenomics: Origins, Definitions and Concepts* Richard M. Weinshilboum, M.D. Professor of Molecular Pharmacology and Experimental Therapeutics and Medicine Mayo Clinic College of Medicine
9:00 – 9:15	Q&A and Discussion

9:15 – 9:45	*Pharmacogenomics: The Public Health Perspective* Robert L. Davis, M.D., M.P.H. Professor, Department of Epidemiology University of Washington School of Public Health
9:45 – 10:05	Q & A and Discussion
10:05 – 10:20	BREAK
10:20 – 10:50	*Pharmacogenomics in the Practice of Medicine* Dr. Weinshilboum
10:50 – 11:10	Q&A and Discussion
11:10 – 11:40	*Perspectives from Industry* Eric Lai, Ph.D. Vice President Discovery and Pipeline Genetics GlaxoSmithKline Walter Koch, Ph.D. Vice President and Head of Research Roche Molecular Systems
11:40 – 12:00	Q&A and Discussion
12:00 p.m. – 12:30 p.m.	Public Comments
12:30 p.m. – 1:30 p.m.	LUNCH
1:30 – 2:00	*HHS Efforts and Future Directions in Pharmacogenomics* Rochelle Long, Ph.D. Chief, Pharmacological & Physiological Sciences Branch National Institute of General Medical Sciences, NIH Felix Frueh, Ph.D. Associate Director for Genomics Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation and Research, FDA Muin Khoury, M.D., Ph.D. Director Office of Genomics and Disease Prevention, CDC
2:00 – 2:20	Q&A and Discussion
2:20 – 2:45	*Ethical, Legal and Social Implications of Pharmacogenomics* Patricia Deverka, M.D., M.S., M.B.E. Fellow

	Center for Genome Ethics, Law & Policy Institute for Genome Sciences & Policy Duke University
2:45 – 3:05	Q&A and Discussion
3:05 p.m. – 3:15 p.m.	BREAK
3:15 – 4:30	Full Committee Discussion and Next Steps for Pharmacogenomics Facilitators: Dr. Willard and Dr. Winn-Deen
4:30 p.m. – 5:00 p.m.	Next Steps and Closing Remarks
	ADJOURN